dual glp 1 glucagon receptor agonists Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Mechanisms of action and therapeutic
Description
4 Clinical evidence in T2DM management A wide range of clinical trials and research have been performed to assess the effectiveness, safety, and tolerability of short-acting against long-acting GLP-1 analogues in the treatment and management of T2DM and obesity

For quantitative synthesis, effect estimates were collected when available, including HRs, 95% CI, and associated p-values

That being said, its crucial to understand that weight loss is a gradual process with semaglutide

12-14 As many patients with T2DM are overweight or obese, a drug that can help patients achieve any amount of weight loss is often welcomed by patients and physicians alike

N Engl J Med (2008) 359:156576
GLP-1s appear to protect against cancer
